Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer.

Seminars in radiation oncology - 1 Apr 2021

Jean-Baptiste Samuel R, Feigenberg Steven J, Dorsey Jay F, Kao Gary D

Abstract excerpt

Recent treatment advances have improved outcomes for patients with non-small cell lung cancer (NSCLC), often utilizing tumor molecular characterization to identify targetable mutations. This is further enhanced by advancements in "liquid biopsies", using peripheral blood for noninvasive, serial sampling of tumor biology. While tumor genomic alterations have established therapeutic implications in metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33610272
DOI: 10.1016/j.semradonc.2020.11.002
PMCID: PMC9889131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer.PMID 33610272Read ↗

Liquid biopsy and its role in an advanced clinical trial for lung cancer.Semantic proximity Read ↗

Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing.Semantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Liquid biopsy tracking of lung tumor evolutions over timeSemantic proximity Read ↗

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Current and future trends in non-small cell lung cancer biomarker testing: The American experience.Semantic proximity Read ↗

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.Semantic proximity Read ↗

The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Semantic proximity Read ↗

Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.Semantic proximity Read ↗

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.